Clinical trial · Observational
Prognostic Performance of the Naples Prognostic Score
The Naples Prognostic Score in Gastric Cancer Patients Undergoing Surgery
NCT03272646CI-TRIAL-00029410NPScompletedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To investigate the prognostic performance of the Naples Prognostic Score in gastric cancer patients undergoing surgery
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Nutritional and Metabolic Diseases | — | UNRESOLVED | — |
| Oncologic Disorders | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| surgery | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- label
- Group 1 or NPS = 0
- description
- Patients undergoing surgery without alterations of the albumin and cholesterol levels, with normal NLR and LMR ratios.
- interventionNames
- Procedure: surgery
- label
- Group 2 or NPS >0 and < 3
- description
- Patients undergoing surgery with NPS between 1 or 2
- interventionNames
- Procedure: surgery
- label
- Group 3 or NPS > 2
- description
- Patients undergoing surgery with three or four alterations
- interventionNames
- Procedure: surgery
Primary outcomes (1)
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * all patients undergoing surgery at our institution for proven gastric adenocarcinoma will be enrolled in the present study Exclusion Criteria: * Patients with lower esophageal adenocarcinoma or cancer crossing the esophagogastric junction with its epicenter in the proximal 2 cm of stomach, which were taken apart from stomach cancers in the last two AJCC cancer staging editions, will be excluded. * Patients with ongoing infections, concomitant immune-mediated diseases, or on drugs capable of affecting neutrophil and/or lymphocyte counts (e.g., steroids, immunosuppressants, etc.) will be excluded from the study.
References
Publications (0)
Data not yet available
No reference posted for this study.